3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
3
Phase 1
2
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Ovarian Neoplasms
18
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
3
Fallopian Tube Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma
2
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Hematologic Neoplasms
1
HER2-ve Metastatic Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
67
Cisplatin
57
Paclitaxel
42
Radiotherapy
35
Pemetrexed
34
Gemcitabine
31
Docetaxel
31
Etoposide
25
pembrolizumab
21
Vinorelbine
20
Erlotinib Hydrochloride
13
Magnetic Resonance Spectroscopy
12
Gefitinib
11
Specimen Handling
10
Radiosurgery
10
Drug Therapy
10
Bevacizumab
10
durvalumab
9
Nivolumab
9
Vinblastine
6
Topotecan
6
Surgical Procedures, Operative
6
Cyclophosphamide
6
atezolizumab
5
Standard of Care
5
Platinum
5
Immunoglobulin G
5
Ifosfamide
5
Disulfides
5
Dexamethasone
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lung Neoplasms
×
olaparib
×
Clear all
NCT04380636
2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
870 enrolled